Collectively engage with lawmakers and key government agencies in the U.S. and Europe (including FDA, CMS, NIH, and EMA) to advance optimal regulatory pathways, a supportive reimbursement framework, and other policies that promote accelerated development and adoption of regenerative medicine products.
Gain exposure to the international investment community through ARM events, presentation opportunities, and ARM’s extensive network.
Provide your organization’s perspective to help shape ARM’s legislative and regulatory priorities and policy positions to address sector opportunities and challenges.
Work with other ARM members and sector colleagues to define, share, and improve approaches for innovative process development, manufacture, control, and distribution of cell and gene medicines and other regenerative therapies.
Collaborate with manufacturing and technology experts to reduce barriers to product development and scale.
Access the most current industry data, including financings, corporate partnerships and acquisitions, clinical trial outlook and overview, and insights into key regulatory and policy changes.
Connect with commercial leaders and potential partners, including therapeutic developers, tool and technology providers, patient advocacy groups, and research institutions, via participation in ARM events and our various Advisory Groups, Forums, and Working Groups.
Present your organization’s accomplishments, priorities, and opportunities to an engaged multi-stakeholder audience at ARM’s many events throughout the year.